A clinical study on modified Wuxiao San in the treatment of intermediate and advanced primary hepatic carcinoma associated with hepatitis B cirrhosis
Objective:To observe the effects of modified Wuxiao San(五消散)on clinical symptoms,TCM symptom scores,liver function test indicators,lesion diameter,lesion volume or area,tumor markers and long-term survival rate of patients with intermediate and advanced primary hepatic carcinoma(PHC)associated with hepatitis B cirrhosis(PHC),and to discuss the clinical effect of modified Wuxiao San in the treatment of intermediate and advanced PHC associated with hepatitis B cirrhosis.Methods:According to the diagnostic criteria and exclusion criteria,96 PHC patients were selected and randomly divided into the control group(48 cases)and the treatment group(48 cases).On the basis of conventional Western anti-hepatitis B virus treatment and hepatic arterial embolization chemotherapy treatment,patients in the control group received Fufang Banmao Jiaonang(复方斑蝥胶囊),while patients in the treatment group received modified Wuxiao San.Four weeks'treatment was one course.After three courses of continuous treatment,the clinical symptoms,TCM score,liver function test index,and long-term survival rate of patients in the two groups were evaluated,and the clinical efficacy in the two groups was compared.Results:In terms of the overall response rate,the total effective rate in the treatment group was 70.83％(34/48),which was significantly higher than 47.92％(23/48)in the control group(P＜0.05).Compared with the control group,the clinical symptoms,TCM symptom score,liver function test indicators,lesion diameter,lesion volume or area,and long-term survival rate in the treatment group were all improved significantly(all P＜0.05).Conclusion:The application of modified Wuxiao San can relieve the clinical symptoms,improve liver function,TCM symptom scores,slow tumor growth,prolong survival in the treatment of PHC patients,and it has a significant therapeutic effect.It is worthy of promotion and application in clinical practice.
Hepatitis B cirrhosisIntermediate and advanced primary hepatic carcinomaWuxiao SanClinical research
万方数据
维普
